The impact of our work

We have received a number of results that have given us information beyond that delivered by standard testing. Results have been returned within standard turnaround times to allow timely reporting.

These have resulted in rapid changes to the treatment and management of several children

Overall, on behalf of the whole clinical team we have been delighted with the impact this is having on patient care, with the added potential this testing offers these children.

Dr Jack Bartram, Consultant Paediatric Haematologist, Great Ormond Street

I have found the DNA and RNA panels highly effective in successfully identifying many de novo and acquired resistance TKI targets for both routine care and trials enrolment.

Professor Sanjay Popat, Lung Consultant Medical Oncologist, The Royal Marsden

We’ve been so grateful for the benefits/improvements the RNA panel has had on Sarcoma Unit patient care, which includes far more precise delineation of rare neoplasms/ disease processes, much greater accuracy (including, importantly, for highlighting potential treatment targets), and always extremely helpful, kind and communicative colleagues/team work. I have been really happy with the turnaround times, always much appreciated!

Dr Khin Thway, Consultant Histopathologist for Sarcoma and Head & Neck unit, The Royal Marsden

It is difficult to overstate how important profiling has become for everyday patient management. For example, the finding of an FGFR fusion means that the patient has the opportunity of highly effective non-chemotherapy treatment that will prolong survival by a year or more. It is difficult to underestimate the importance of this to patients who have often been given a poor prognosis.

Professor John Bridgewater, Consultant Medical Oncologist and Clinical Researcher at UCL Cancer Institute

We are delighted to announce the partnership with Guardant Health, establishing a state-of-the-art liquid biopsy testing facility. In a clinical diagnostic setting, it will provide many of our patients with more rapid access to bespoke diagnostic testing, leading to earlier, faster, and more accurate diagnosis, along with targeted treatment selection and monitoring.

The opening of this service will also allow us to significantly increase our capacity for research using liquid biopsies. Bringing expanded capacity for genomic testing, the facility will help us identify more people with cancer for clinical trials based on targeted treatments, improving outcomes for patients across the UK and beyond.

Professor Michael Hubank, Scientific Director (Genomics) at The Royal Marsden and Professor of Translational Genomics at the Institute of Cancer Research, London